KIAA1324 and its mutants were cloned into the pCMV-3HA vector (Clontech, California, USA) as previously described [13 (link)]. Asp (N) to Gln (Q) amino acid exchange mutation in putative N-glycosylation sites was performed by a DpnI-site directed mutagenesis method using mutagenic primers [21 (link)]. Anti-HA (Santa Cruz Biotechnology, Texas, USA, sc-7392) and anti-PARP (Santa Cruz Biotechnology, sc-8007), anti-caspase-3 (Cell Signaling Technology, Massachusetts, USA, #9662), anti-caspase-7 (Cell Signaling Technology, #9494), anti-phosphor-JNK (Cell Signaling Technology, #4668), anti-JNK (Cell Signaling Technology, #9252), anti-GRP78 (Abcam, Cambridge, United Kingdom, ab21685), anti-PDI, anti-β-actin (Abcam, ab8227), anti-KIAA1324 (Sigma, Missouri, USA, SAB2900912) and α-tubulin (Sigma, T5168) antibodies were used. 2F-Peracetyl-Fucose (Sigma, #344827), SP600125 (Sigma, S5567), SB203580 (Sigma, S8307), U0126 (Sigma, U120), tunicamycin (Sigma, T7765), and doxycycline (Sigma, #24390-14-5) chemicals were used.
Free full text: Click here